A Phase III randomized controlled trial comparing the efficacy, safety and tolerability of oral dydrogesterone versus micronized vaginal progesterone for luteal support in in vitro fertilization

Hum Reprod 2017;32:1019–1027

The authors would like to apologise for an error in the Materials and Methods section of this article. The suppliers of the placebo in Group 1 and Group 2 patient groups are incorrect. The placebo intravaginal capsules given to Group 1 patients are from Catalent (Germany). The oral placebo tablets given to Group 2 patients are from Abbott B.V. (The Netherlands).

The authors would like to assure readers that this does not affect any content of the article.